The Study
Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease
This study is like watching 13 people take a medicine and checking their blood levels at certain times. It tells us how the drug moves through their bodies, but it doesn’t prove the drug helps with Alzheimer’s or works better than other treatments.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
This study looked at how a drug called rapamycin behaves in the blood of people with early Alzheimer's when taken once a week.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 544 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The drug doesn’t build up to levels that cause strong immune suppression, which is good for safety in long-term use.
- 2After a weekly 7 mg dose, rapamycin stays in the body for about 69 hours on average.
- 3The best time to check blood levels is 48 hours after the dose.
- 4All patients had very low levels just before the next dose—below 2 ng/mL.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
GeroScience
Year
2025
Authors
Helen Annervik Wallgren, M. Kivipelto, P. Plavén-Sigray, J. Svensson
Related Content
Claims (6)
Sirolimus stays in your body for a long time—about 2.5 days—so even if you take it just once a week, it might still be active when you work out again.
Taking a weekly 7 mg dose of rapamycin for early Alzheimer's doesn't vary too much from person to person, so doctors might not need to adjust doses or monitor blood levels in future studies.
For people with early Alzheimer’s taking a weekly 7 mg rapamycin pill, checking their blood 48 hours after the dose gives the most consistent results and best predicts their baseline levels—so that’s the best time to test it.
When people with early Alzheimer's take rapamycin once a week, the drug stays in their body about as long as it does in other groups — around 69 hours — which means it leaves the body at a similar rate even with weekly dosing.
People with early Alzheimer’s who take 7 mg of rapamycin every week seem to have low levels of the drug in their blood before their next dose—so low that it probably won’t weaken their immune system.
The tools we use to measure rapamycin in the fluid around the brain aren't sensitive enough to catch the tiny amounts that actually get there, so we can't tell if it's really crossing into the brain in people.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.